Video Experimental Relacionado
Updated: Jan 13, 2026
06:03
Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
9.6K
Terapias basadas en ARN para el tratamiento de miocardiopatías monogénicas
Jonathan J Edwards1, Jonathan B Edelson2, Joseph Rossano1
1Department of Pediatrics, Division of Cardiology; Cardiovascular Institute, Children's Hospital of Philadelphia.
The Canadian journal of cardiology
|January 9, 2026
Resumen
Las terapias basadas en ácido ribonucleico (ARN) prometen para las afecciones cardíacas genéticas como las miocardiopatías. Los avances en los sistemas de administración son clave para superar los desafíos y permitir la medicina cardiovascular de precisión.
Área de la Ciencia:
- Medicina Cardiovascular
- Genética
- Biología Molecular
Sus antecedentes:
- La medicina cardiovascular de precisión está avanzando rápidamente.
- Las miocardiopatías monogénicas son un objetivo para nuevas terapias genéticas.
- Los productos terapéuticos basados en ácido ribonucleico (ARN) ofrecen nuevas estrategias de tratamiento.
Objetivo del estudio:
- Revisar el potencial de varios productos terapéuticos basados en ARN para miocardiopatías monogénicas.
- Destacar el progreso reciente en los sistemas de administración de ARN.
- Identificar desafíos y direcciones futuras para las terapias de ARN en medicina cardiovascular.
Principales métodos:
- Revisión de la literatura actual sobre terapias basadas en ARN.
- Análisis de diferentes clases de terapias de ARN (p. ej., oligonucleótidos antisentido, microARNs, ARNi, ARNh, ARNc largos).
- Evaluación de sistemas de administración virales y no virales.
Principales resultados:
- Múltiples clases de terapias de ARN están bajo investigación para miocardiopatías genéticas.
- El progreso en los sistemas de administración mejora la viabilidad de los tratamientos basados en ARN.
- Las aplicaciones se extienden a trastornos genéticos como la distrofia muscular de Duchenne y la miocardiopatía hipertrófica.
Conclusiones:
- Las terapias de ARN tienen un potencial significativo para el tratamiento de miocardiopatías monogénicas.
- Superar los desafíos en durabilidad, respuesta inmune y administración es crucial.
- Las terapias basadas en ARN están preparadas para convertirse en un elemento central de la medicina cardiovascular de precisión.
Videos de Conceptos Relacionados
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
444
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
444
01:29Cardiomyopathy V: Interprofessional Care
331
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
331
01:30Cardiomyopathy II: Dilated Cardiomyopathy
457
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
457
01:25Cardiomyopathy I: Introduction and Classification
492
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
492
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
393
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
393
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K